Company intelligence / Profile preview

ApcinteX Ltd.

Altrincham, Cheshire, United Kingdomorpha.net ↗

Ownership: Private
Development stage: Phase 2

Overview

SerpinPC demonstrated safety and tolerability in healthy volunteers and hemophilia patients. It showed potential to reduce bleeding episodes by inhibiting activated protein C rather than replacing missing coagulation factors. This novel mechanism addresses limitations of current factor replacement therapies, including inhibitor development. The drug was well tolerated at high doses in animal models with significant reduction of blood loss.

Therapeutic areas: Hematology
Modalities: Protein therapeutics
Industry: Biotech

Drug pipeline

1 asset

serpinPC

Phase 2

Indications: Hemophilia A, Hemophilia B

Partnerships

Part of Centessa’s portfolio alongside other biotech companies under centralized management

Beyond the preview

Go deeper on ApcinteX Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ApcinteX Ltd..

Explore the full profile